Premium
The role of radiation therapy in the management of plasma cell tumors
Author(s) -
Mill William B.,
Griffith Rogers
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800215)45:4<647::aid-cncr2820450405>3.0.co;2-e
Subject(s) - medicine , multiple myeloma , plasmacytoma , radiation therapy , incidence (geometry) , surgery , plasma cell neoplasm , retrospective cohort study , radiology , nuclear medicine , optics , physics
A retrospective review is reported of 128 patients presenting with multiple myeloma and 16 patients presenting with solitary plasmacytoma. Ninety‐one percent of 116 evaluable patients treated for palliation of painful bone disease received some degree of subjective pain relief. The radiation dose most frequently prescribed was between 1500 and 2000 rad. Of the 278 ports treated, only 17 (6.1%) were re‐treated to the same area at a later date. There was no increase in incidence of re‐treatment with lower radiation doses. Ten of the 13 patients treated for a solitary plasmacytoma with a minimum follow‐up period of three years have local tumor control. The median survival in the solitary plasmacytomas is five and one‐half years. Data from the literature on 27 additional solitary plasma‐cytomas combined with our data suggest an improved local control and a decrease in dissemination with doses greater than 5000 rad. It is concluded that low doses of radiation are usually adequate to treat painful bone lesions of multiple myeloma and doses of 5000–6500 rad in six to seven weeks are recommended for solitary plasmacytomas. Cancer 45:647‐652, 1980.